The relationship between the serotonergic system and COVID-19 disease: A review

Eteraf-Oskouei, Tahereh; Najafi, Moslem

doi:10.1016/j.heliyon.2022.e09544

Cited by 14 publications

(11 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… In vitro Meroni, Barcellini, Borghi, Vismara, Ferraro, Ciani, Zanussi [11] Lymphocyte Blastogenesis Silybin,0.5, 10, and 25 μM silybin on activating human T lymphocytes and observed that silybin significantly reduce the proliferative reaction to the monoclonal anti-CD3 antibody in a dose-dependent manner In vitro Hawke, Schrieber, Soule, Wen, Smith, Reddy, Wahed, Belle, Afdhal, Navarro, Berman, Liu, Doo, Fried [12] 32 patients with chronic HCV infection Silymarin, 140, 280, 560, or 700 mg clinically meaningful reductions from baseline serum transaminases or HCV RNA titer were observed. Case report Payer et al, 2010 13 A case of an HIV-HCV coinfected patient Administration of silibinin: 20 mg/kg/day for 14 days intravenously Inhibition of HIV replication; a decrease in HCV RNA and HIV RNA Clinical trial Yakoot et al [14] 66 patients with chronic HCV infection Administration of silymarin: 140 mg 3 times daily for 6 months No virological response in the 96.6 % of silymarin treated group Clinical trial Biermer et al [15] 20 patients with chronic HCV Administration of silibinin: 1400 mg daily, infusion on 2 consecutive days Complete viral suppression in 13 of 20 patients; remaining HCV RNA negative during the subsequent follow up period Clinical trial Adeyemo et al [16] 32 patients with chronic HCV Administration of silymarin: 420 mg 3 times daily and 700 mg 3 times daily for 20 weeks No alteration in serum ALT and HCV RNA titers; suppression of C. albicans-induced T-cell IFNγ and phytohemagglutinin-induced T-cell proliferation; modest non-specific immunomodulatory effects in vivo by silymarin administration COVID-19 related article Molecular docking analysis Latha et al [17] Phytochemicals from the medicinal plants Docking analysis Better binding affinity to the target proteins of SARS-COV-2 than the synthetic repurposed drugs for treatment of COVID-19 Molecular docking analysis Saraswat, Singh, Patel [18] Phytochemicals from the medicinal plants ...…”

Section: Resultsmentioning

confidence: 99%

“…In this regard, critically ill patients with COVID-19 have displayed higher levels of neutrophils, pro-inflammatory cytokines, and ROS [14] . The latter, in turn, is thought to be associated with endothelial cell dysfunction, impaired immune response, and platelet aggregation, which all exacerbate the severity of COVID-19 patients [15] . In the present emergent situation, drug repositioning from approved and well-known complementary medicine for developing possible therapeutic and prophylactic agents may be cost-effective [16] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms

Musazadeh

Karimi²,

bagheri³

et al. 2022

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms

Musazadeh

Karimi²,

bagheri³

et al. 2022

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…Other metabolites interacting with IL-6 included serotonin, a neurotransmitter, known to play important roles in the immune system and in regulating inflammatory responses (79). From the data-driven seeds (Table 1), we observed that STAT1 established connections with hubs IRF1, and CCL4 in mild, and hub IRF1 in both moderate and severe disease states.…”

Section: Discussionmentioning

confidence: 96%

“…Taurine levels have been reported to decrease in COVID-19 patients which potentially modulates disease progression via its antiviral, antioxidant, anti-inflammatory, and vascular-related effects (78). Other metabolites interacting with IL-6 included serotonin, a neurotransmitter, known to play important roles in the immune system and in regulating inflammatory responses (79).…”

Section: Discussionmentioning

confidence: 99%

Network-based integrative multi-omics approach reveals biosignatures specific to COVID-19 disease phases

Agamah,

Ederveen,

Skelton

et al. 2023

Preprint

View full text Add to dashboard Cite

BackgroundCOVID-19 disease is characterized by a spectrum of disease phases (mild, moderate, and severe). Each disease phase is marked by changes in omics profiles with corresponding changes in the expression of features (biosignatures). However, integrative analysis of multiple omics data from different experiments across studies to investigate biosignatures at various disease phases is limited. Exploring an integrative multi-omics profile analysis through a network approach could be used to determine biosignatures associated with specific disease phases and enable the examination of the relationships between the biosignatures.AimTo identify and characterize biosignatures underlying various COVID-19 disease phases in an integrative multi-omics data analysis.MethodWe leveraged the correlation network approach to integrate transcriptomics, metabolomics, proteomics, and lipidomics data. The World Health Organization (WHO) Ordinal Scale (WOS) was used as a disease severity reference to harmonize COVID-19 patient metadata across two studies with independent data. A unified COVID-19 knowledge graph was constructed by assembling a disease-specific interactome from the literature and databases. Disease-state omics-specific graphs were constructed by integrating multi-omics data with the unified COVID-19 knowledge graph. We expanded on the network layers of multiXrank, a random walk with restart on multilayer network algorithm, to explore disease state omics-specific graphs and perform enrichment analysis.ResultsNetwork analysis revealed the biosignatures involved in inducing chemokines and inflammatory responses as hubs in the severe and moderate disease phases. We observed more shared biosignatures between severe and moderate disease phases as compared to mild-moderate and mild-severe disease phases. We further identified both biosignatures that discriminate between the disease states and interactions between biosignatures that are either common between or associated with COVID-19 disease phases. Interestingly, cross-layer interactions between different omics profiles increased with disease severity.ConclusionThis study identified both biosignatures of different omics types enriched in disease-related pathways and their associated interactions that are either common between or unique to mild, moderate, and severe COVID-19. These biosignatures include molecular features that underlie the observed clinical heterogeneity of COVID-19 and emphasize the need for disease-phase-specific treatment strategies. In addition, the approach implemented here can be used for other diseases.Key findings⍰Integrative multi-omics analysis revealed biosignatures and biosignature interactions associated with COVID-19 disease states.⍰Disease severity increases with biosignature interactions across different multi-omics data.⍰The harmonization approach proposed and implemented here can be applied to other diseases

show abstract

“…The depletion of ACE2 by SARS-CoV-2 can directly interrupt or inhibit the activation of psychoneuroendocrine pathways related to PTSD, anxiety, and depression. This process occurs by the massive secretion at the systemic level and in the CNS, of several pro-inflammatory cytokines, such as IL-2, IL-6, TNF-α, and interferon-gamma (IFN-γ), which compromise the synthesis, release, and the reuptake of some neurotransmitters, including dopamine, norepinephrine, and serotonin (61,62) .…”

Section: Role Of the Neuroendocrine-immune Axis In Psychiatric Disordersmentioning

confidence: 99%

Post-traumatic stress disorder, anxiety and depression in post-COVID19 patients: integrative review

Carrijo

Faria²,

Palma³

et al. 2022

mtprehabjournal

View full text Add to dashboard Cite

Background: Global estimates point to high prevalence of neuropsychiatric disorders in individuals hospitalized for COVID-19. In Brazil, anxiety and depression rates resulting from SARS-CoV-2 infection range from 29.7% to 68%, respectively, being more prevalent in young women, with lower educational level, with comorbidities and psychological problems. previous. Objective: Identify possible causes, verify prevalence and identify risk factors for anxiety, depression and post-traumatic stress disorder (PTSD) in patients hospitalized for COVID-19. Methods: An integrative literature review was carried out involving retrospective and/or prospective cohort studies and population-based clinical trials published in the last three years. The main evidence on the relationship between neuropsychiatric disorders and intrinsic changes in neuroimmunomodulation parameters was also raised. Results: Twenty-one studies were included that addressed the presence of symptoms of PTSD, anxiety, depression, fatigue in sleep disorders in COVID19 survivors. Conclusion: With this literature review, it can be concluded that PTSD, anxiety, depression, fatigue and sleep disturbances are highly prevalent symptoms in COVID-19 survivors, being persistent for up to one-year post-infection.

show abstract

The relationship between the serotonergic system and COVID-19 disease: A review

Cited by 14 publications

References 72 publications

The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms

The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms

Network-based integrative multi-omics approach reveals biosignatures specific to COVID-19 disease phases

Post-traumatic stress disorder, anxiety and depression in post-COVID19 patients: integrative review

Contact Info

Product

Resources

About